Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 4/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | ESRRB | O95718 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818064 | 0.95 | ESR1 (0.56) | ESR1ESR2CNR2SMPD1CYP19A1 | |
| SCHEMBL4666434 | 0.93 | ESR1 (0.51) | ESR1ESR2CNR2SMPD1CYP19A1 | |
| SCHEMBL4896555 | 0.93 | ESR1 (0.54) | ESR1ESR2CNR2SMPD1CYP19A1 | |
| SCHEMBL5052671 | 0.89 | ESR1 (0.51) | ESR1ESR2CNR2SMPD1CYP19A1 | |
| SCHEMBL3817125 | 0.88 | ESR1 (0.54) | ESR1ESR2CNR2SMPD1CYP19A1 | |
| SCHEMBL4665860 | 0.88 | CYP19A1 (0.57) | ESR1ESR2CNR2SMPD1CYP19A1 | |
| SCHEMBL5004320 | 0.87 | ESR1 (0.52) | ESR1ESR2CNR2ESRRGESRRB | |
| SCHEMBL4667623 | 0.87 | ESR1 (0.52) | ESR1ESR2CNR2SMPD1PTGS2 | |
| SCHEMBL5075263 | 0.83 | THRA (0.56) | ESR1ESR2ESRRGESRRB | |
| SCHEMBL3814114 | 0.83 | ESR1 (0.52) | ESR1ESR2CNR2SMPD1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| WO-2007062145-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ESR1 4/4885ESR2 2/4885CNR2 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.